ConductScience.org, home

Paper39115191

Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer.

Werner B and 9 others. Mol Oncol, 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer. Papers, record 39115191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39115191

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer.
PubMed
Journal
Mol Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.25, provisional
iCite
Revised in PubMed
2026-07-01
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Werner BBonnitahttps://orcid.org/0000-0001-5208-1613
2Powell EElyse
3Duggan JJennifer
4Cortesi MMarilisa
5Lee YCYeh Chen
6Arora VVivek
7Athavale RRamanand
8Dean MMichaelhttps://orcid.org/0000-0003-2234-0631
9Warton KKristina
10Ford CECaroline Ehttps://orcid.org/0000-0002-4438-2309

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
AscitesMajor topic
Cell-Free Nucleic AcidsMajor topic
Humans
Female
Mutation
Middle Aged
DNA Copy Number Variations
Aged
Loss of Heterozygosity
High-Throughput Nucleotide Sequencing
Biomarkers, Tumor

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
NIHPubMed
Australian Academy of SciencePubMed

Source PubMed

Download CSV of grants

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131344859Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature.Cancers (Basel)2019https://conductscience.org/library/papers/31344859PubMed
233302872PyClone-VI: scalable inference of clonal population structures using whole genome data.BMC Bioinformatics2020https://conductscience.org/library/papers/33302872PubMed
315374957Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.Cancer Res2004https://conductscience.org/library/papers/15374957PubMed
437932736Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.Mol Cancer2023https://conductscience.org/library/papers/37932736PubMed
533233347Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.Cancers (Basel)2020https://conductscience.org/library/papers/33233347PubMed
637597580Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2023https://conductscience.org/library/papers/37597580PubMed
730380390Application of Cell-free DNA Analysis to Cancer Treatment.N Engl J Med2018https://conductscience.org/library/papers/30380390PubMed
838097143The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.Biochim Biophys Acta Rev Cancer2024https://conductscience.org/library/papers/38097143PubMed
929592813Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.Genome Med2018https://conductscience.org/library/papers/29592813PubMed
1037700064The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review.Br J Cancer2023https://conductscience.org/library/papers/37700064PubMed
1133506580Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.J Obstet Gynaecol Res2021https://conductscience.org/library/papers/33506580PubMed
1234069200Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.Cancers (Basel)2021https://conductscience.org/library/papers/34069200PubMed
1328916367Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017https://conductscience.org/library/papers/28916367PubMed
1434454680Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.Gynecol Oncol2021https://conductscience.org/library/papers/34454680PubMed
1520818904Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.N Engl J Med2010https://conductscience.org/library/papers/20818904PubMed
1632496546SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update).Nucleic Acids Res2020https://conductscience.org/library/papers/32496546PubMed
1721720365Integrated genomic analyses of ovarian carcinoma.Nature2011https://conductscience.org/library/papers/21720365PubMed
1836849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023https://conductscience.org/library/papers/36849657PubMed
1926017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015https://conductscience.org/library/papers/26017449PubMed
2031722153Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.N Engl J Med2019https://conductscience.org/library/papers/31722153PubMed

See all 36 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42786656Circulating tumour cells for guiding antibody‒drug conjugate therapy: Role of artificial intelligence.Clin Transl Med2026https://conductscience.org/library/papers/42786656PubMed
42366335Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids.Clin Proteomics2026https://conductscience.org/library/papers/42366335PubMed
41413429Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing.Sci Rep2025https://conductscience.org/library/papers/41413429PubMed
41363274Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.Int J Cancer2026https://conductscience.org/library/papers/41363274PubMed
41244344Development and validation of a computational tool to predict treatment outcomes in cells from high-grade serous ovarian cancer patients.Bioeng Transl Med2025https://conductscience.org/library/papers/41244344PubMed
41088281Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics.Mol Cancer2025https://conductscience.org/library/papers/41088281PubMed
40278372Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling in the ES-2 Ovarian Carcinoma Cell Line, Influencing Cell Proliferation, Quiescence, and Chemoresistance in a Cell-of-Origin-Specific Manner.Metabolites2025https://conductscience.org/library/papers/40278372PubMed
40051502Immunomagnetic enrichment coupled to PAX8/TP53 molecular pathology approach increases sensitivity in the detection of ovarian cancer cells in ascites.Front Mol Biosci2025https://conductscience.org/library/papers/40051502PubMed
39591206Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.Cancer Res Commun2024https://conductscience.org/library/papers/39591206PubMed
39221267Beyond 2D cell cultures: how 3D models are changing the in vitro study of ovarian cancer and how to make the most of them.PeerJ2024https://conductscience.org/library/papers/39221267PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39115191

GET https://conductscience.org/api/papers/v1/39115191/references?page=2